Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to: Comment on "The optimal labelling method for artificial intelligence-assisted polyp detection in colonoscopy".

Journal of the Formosan Medical Association = Taiwan yi zhi·2026
Same author

Role of hippocampal subfield volumes in the efficacy of transcranial direct current stimulation for late-life depression: An exploratory pilot randomized clinical trial.

Behavioural brain research·2025
Same author

Bali Chronic Constipation Roundtable Report: Chronic Constipation Management in Asia.

Journal of neurogastroenterology and motility·2025
Same author

The influences of antihistamine on liver fibrosis, vasoresponsiveness, and portosystemic shunting in bile duct-ligated cirrhotic rats.

Journal of the Chinese Medical Association : JCMA·2025
Same author

Time-restricted feeding attenuates hepatic inflammation and enhances muscular endurance of biliary cirrhotic rats.

Life sciences·2025
Same author

Clinical impact of pharmacogenetic risk variants in a large chinese cohort.

Nature communications·2025

Related Experiment Video

Updated: Mar 6, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A

Fu-Ming Chang1,2,3, Yen-Po Wang1,3,4,5, Hui-Chu Lang6

  • 1Division of Gastroenterology, Taipei Veterans General Hospital, Taipei, Taiwan.

Hepatology (Baltimore, Md.)
|March 21, 2017
PubMed
Summary

Statin use significantly lowers the risk of decompensation, mortality, and liver cancer in patients with cirrhosis from hepatitis B or C. Benefits were dose-dependent and observed in a large Taiwanese cohort.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

7.2K

Related Experiment Videos

Last Updated: Mar 6, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

7.2K

Area of Science:

  • Hepatology
  • Clinical Pharmacology
  • Gastroenterology

Background:

  • Statin use is known to reduce decompensation and mortality in hepatitis C virus (HCV) related cirrhosis.
  • The effects of statins on cirrhosis from other causes like hepatitis B virus (HBV) or alcohol are not well-established.
  • Statin's role in preventing hepatocellular carcinoma (HCC) in patients with pre-existing cirrhosis is also unclear.

Purpose of the Study:

  • To investigate the impact of statin use on decompensation, mortality, and HCC rates in patients with HBV, HCV, and alcohol-related cirrhosis.
  • To determine if statin's benefits extend beyond HCV-related cirrhosis to other etiologies.
  • To assess the dose-response relationship between statin use and these adverse outcomes.

Main Methods:

  • A cohort of 1350 patients with cirrhosis was identified from Taiwan's National Health Insurance beneficiaries (2000-2013).
  • Statin users (cumulative defined daily dose [cDDD] ≥28) were compared with matched non-users (<28 cDDD) using propensity scores.
  • The association between statin use and risks of decompensation, mortality, and HCC was analyzed using regression models.

Main Results:

  • Statin use demonstrated a dose-dependent reduction in decompensation, mortality, and HCC risk among all cirrhosis patients.
  • Significantly lower decompensation risk was observed in statin users with HBV-related (HR 0.39) and HCV-related (HR 0.51) cirrhosis.
  • A trend towards reduced decompensation risk was noted for alcohol-related cirrhosis (HR 0.69), though not reaching statistical significance.

Conclusions:

  • Statin therapy effectively decreases decompensation rates in both HBV- and HCV-related cirrhosis.
  • A potential, though not statistically significant, benefit in reducing decompensation was observed for alcohol-related cirrhosis.
  • Findings support the broader application of statins in managing cirrhosis patients across different etiologies.